Global Biotech Weekly

This week, we will focus on key Phase 3 catalysts left for the quarter anticipated in the immediate term over the next two months. Reviva Pharmaceuticals (NASDAQ: RVPH) is a clinical-stage biopharmaceutical company with a market cap under US$100m. The company is focused on developing therapies targe Brilaroxazine is being developed for schizophrenia, with results from the Phase 3 RECOVER trial showing broad-spectrum efficacy and a favorable long-term safety profile. NovoCure (NASDAQ: NVCR) is a commercial-stage oncology company with a market cap in the mid-single-digit billions, known for its Tumor Treating Fields (TTFields) platfor NovoCure’s Phase 3 PANOVA-3 trial evaluated TTFields combined with nab-paclitaxel and gemcitabine for locally advanced pancreatic cancer. Final results released in Decem Gossamer Bio (NASDAQ: GOSS) is a clinical-stage biopharmaceutical company focused on developing therapies for pulmonary diseases. The company has a small market cap unde Seralutinib is currently being evaluated in the Phase 3 PROSERA trial for PAH, following positive results from the Phase 2 TORREY study, which met its primary endpoint. InflaRx N.V. (NASDAQ: IFRX) is a clinical-stage biotech developing anti-inflammatory therapeutics, with a focus on complement factor C5a inhibition. The company has a sm Vilobelimab is in a pivotal Phase 3 trial for pyoderma gangraenosum (PG), a rare neutrophilic dermatosis. The ongoing study follows a promising Phase 2a dose-finding tri